AstraZeneca

News

Pathos AI has grown its oncology pipeline by licensing a bispecific ADC from Alphamab for $125m and partnering a breast cancer drug from AstraZeneca.

News

There are rumours that the first pharma 'mega-merger' for several years – between AstraZeneca and Bristol Myers Squibb – is under discussion.

News

AstraZeneca and Daiichi Sankyo's Datroway enters the first-line triple-negative breast cancer market in the EU, taking on Gilead's Trodelvy.

News

AstraZeneca has served up a robust set of interim results, leavened by strong sales of cancer drugs, but with some mixed pipeline news on the side.

News

AstraZeneca's new breast cancer therapy Etcamah claims landmark frontline approval in the EU, but its prospects in the US are less certain.

News

AstraZeneca has continued its pipeline-boosting deal spree in China with a $1.5bn licensing deal for Dizal Pharma's lung cancer therapy Zegfrovy.